IMMUNOMODULATING COMPOSITION CONTAINING GASSERI

    公开(公告)号:US20250009817A1

    公开(公告)日:2025-01-09

    申请号:US18417720

    申请日:2024-01-19

    Abstract: Provided is an immunomodulatory treatment composition for a transplantation disease through combined administration of a microbiome and an immunosuppressant. According to the present disclosure, it was confirmed that in an allogeneic transplantation cell model, combined administration of FK506 and the microbiome suppressed alloresponse and regulated the activity of T cells and B cells. Further, it was confirmed that in an acute graft-versus-host disease animal model, the combined administration reduced the disease activity, increased the probability of survival, and protected the tissue damage. In addition, it was confirmed that the combined administration improved transplantation rejection diseases by reducing the activity of Th1 and Th17 and increasing the activity of Tregs, and thus can be usefully used as an immunomodulator for transplantation rejection.

    EXTRAMAMMARY PAGET DISEASE BIOMARKERS AND USES THEREOF

    公开(公告)号:US20240377415A1

    公开(公告)日:2024-11-14

    申请号:US18658276

    申请日:2024-05-08

    Inventor: Young-Bok LEE

    Abstract: The present invention relates to extramammary Paget disease biomarkers, such as SPDEF, ARG2, and ABEP1, and uses thereof that were discovered by exploring the molecular profile as well as performing a comprehensive genetic analysis of EMPD. The present invention investigates how EMPD evolves in the context of treatment and may elucidate a potential mechanism of progression to invasion. Furthermore, the biomarkers of the present invention may be usefully used in the diagnosis or treatment of extramammary Paget disease in that the tissue microenvironments and cell types associated with EMPD may be further characterized using spatial transcriptomics.

Patent Agency Ranking